Buc-ee's founder fuels Texas A&M's new $50M immersive learning laboratory

Beaver powered

Buc-ee's founder Arch Aplin III is gifting $50M to A&M's new facility. Buc-ee's/Facebook

The founder of Lone Star State’s favorite rest stop/gas station/car wash/cultural beacon has just made a Texas-sized investment in a major state university.

Buc-ee’s mastermind Arch “Beaver” Aplin III will commit $50 million toward establishing a Texas A&M University academic center that will serve as an immersive learning laboratory, the school announced.

Dubbed the Aplin Center (Aplin graduated from A&M in 1980), the hub will offer new university programs in hospitality, retail studies, and food product development through degree programs including viticulture, fermentation processes, coffee, and food science.

This new facility also will house product development laboratories and food tasting centers that can be utilized in partnership with related industries, according to a press release. Retail and food services areas will be managed by students and faculty. Students can also expect indoor and outdoor recreational spaces.

The center will be built across the street from the Texas A&M Hotel and Conference Center near Wellborn Road and Kyle Field.

Aplin’s $50 million commitment marks one of the largest single donations in Texas A&M history. “Arch ‘Beaver’ Aplin is a true visionary and one of the most creative entrepreneurs I have known,” said school president Dr. M. Katherine Banks in a statement. “He remains connected to his university, speaking to many students who share his passion for business and product development. Through this generous gift, he is creating a living, learning laboratory that will provide transformational opportunities for our students. The Aplin Center will positively impact Aggies for generations to come.”

Buc-ee’s founder, in turn, noted that Banks’ vision of a “world-class hospitality entrepreneurship program” is “just what Texas A&M needs and I’m proud to have an opportunity to be involved.”

Two years after graduation, Aplin opened his first Buc-ee’s in 1982 in Lake Jackson. His beaver empire has since expanded into five other states, with development underway in another five. Aplin’s brand hallmarks include pristine restrooms, endless fuel pumps, a vast selection of food and consumer items.

Besides its reputation as a cult and customer favorite, Buc-ee’s offers health insurance to employees and pays more than twice the amount of minimum wage. Earlier this year, the convenience store-rest stop hybrid received nationwide attention on CBS Sunday Morning. July 28 marks Buc-ee’s 40th anniversary.

“When Beaver Aplin does something, it’s never halfway,” said A&M System chancellor John Sharp in a statement. “The love he has and shows for Texas A&M and Aggies is inspirational and appreciated. This is an awesome gift and will position Texas A&M to become the top hospitality program in the nation.”

An Aggie through and through, Aplin, who serves on myriad boards and is also chairman of Texas Parks and Wildlife, once preached the College Station gospel during a lecture in 2012, telling the class, “I have to remember — I’ve gotta stay Beaver. I’ve gotta stay Buc-ee’s. I’ve gotta stay Aggie and I’ve gotta stay who I am.”

------

This article originally ran on CultureMap.

This makes those Beaver Nuggets a lot more cost effective. Image courtesy of TDECU

Houston-area credit union pumps up customers with new Buc-ee’s credit card

WHO NEEDS A BLACK CARD?

Buc-ee’s fanatics, rejoice! As consumers cope with skyrocketing prices, those Beaver Nuggets and gas purchases are getting cheaper for certain credit card holders.

A new credit card from Houston-area credit union TDECU offers a five percent discount for in-store and at-the-pump Buc-ee’s purchases made with the card. TDECU says holders of the new Buc-ee’s Platinum Mastercard, featuring the iconic Buc-ee’s logo, can take advantage of the discount at participating Buc-ee’s locations.

“We are thrilled to share the expanded benefit of our Buc-ee’s partnership with our Members, at a time when they need it most,” Isaac Johnson, president and CEO of TDECU, says in a news release. “Buc-ee’s travel centers have become their own must-see destinations, and we are excited to give our Members another reason to stop along their financial journeys.”

TDECU members with other Mastercard or Visa credit cards will continue to receive a 10-cents-a-gallon discount on fuel pumped at Buc-ee’s stores.

Both Buc-ee’s and TDECU are based in Lake Jackson.

Buc-ee’s operates 35 stores in Texas and locations in seven other states. Its stores are known for their massive size, spotless restrooms, and Beaver Nuggets snacks.

TDECU (Texas Dow Employees Credit Union) is the largest credit union in the Houston area. It operates 37 branches in the region.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings